<DOC>
	<DOCNO>NCT00210756</DOCNO>
	<brief_summary>The purpose study describe pharmacokinetics ( PK ) six different dose regimen epoetin alfa ( PROCRITÂ® ) anemic critically ill subject</brief_summary>
	<brief_title>Pharmacokinetic/ Pharmacodynamic Study Epoetin Alfa ( PROCRIT ) Critically Ill Patients .</brief_title>
	<detailed_description>Currently , optimal dose regimen achieve maintain target Hb concentration various clinical setting remain incompletely define . Both IV SC rout administration use clinical set show effective despite different bioavailability pharmacokinetic profile . This study design describe pharmacokinetic pharmacodynamic profile several different epoetin alfa dose regimen administer IV SC rout anemic critically ill patient admit critical care area . The dosing regimens select compare among 40,000 IU SC weekly dose regimen ( A ) use large registration trial . Specifically , six dose regimen select gather PK PD data follow question : 1 ) Will early large Cmax , achieve IV dosing , stimulate reticulocytosis ? ( IV vs. SC dose regimens A vs. B , C vs. D , E vs. F ) ; 2 ) Do small frequent dos total dose result PD profile ? ( A vs. C , B vs. D ) ; 3 ) Does IV load improve PD response ? ( E F vs. C D ) ; 4 ) Do large frequent loading dos accumulate ? ( A vs. E B vs. F ) . Results study provide pharmacokinetic foundation understand potentially maximize pharmacodynamic effect different dose option critically ill patient . In order maximize subject safety , dose cease subject 's hemoglobin &gt; 13g/dL . Group A:40 K SC Qw : Days 1,8,15 ; Group B:40 K IV Qw : Days 1,8,15 ; Group C:15 K SC QOD : Days 1,3,5,7,9,11,13,15 ; Group D:15 K IV QOD : Days 1,3,5,7,9,11,13,15 ; Group E:40 K SC Days 1 3 , 15 K SC QOD : Days 5,7,9,11,13,15 ; Group F : 40 K IV Days 1 3 , 15 K SC QOD : Days 5,7,9,11,13,15</detailed_description>
	<mesh_term>Critical Illness</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>Critically ill subject admit critical care area medical diagnosis , ( nonsurgical , nontrauma ) without evidence acute blood loss Critically ill subject develop medical diagnosis surgery trauma evidence active bleeding within prior week current transfusion need Expected hospital stay &gt; = 7 day beyond study entry , age &gt; =18 year Hb : &lt; =12 g/dL . Primary admit diagnosis critical care area acute ischemic cardiac disease ischemic neurological disease ( include limit myocardial infarction unstable angina , transient ischemic attack , cerebrovascular event ) History deep vein thrombosis ( DVT ) pulmonary embolism ( PE ) Iron deficiency ( define serum ferritin &lt; 50 micrograms/L ) History untreated chronic B12 Folate deficiency ( e.g . pernicious anemia ) . Patients B12 folate deficiency treat currently may enter study Renal failure dialysis , include continuous renal replacement therapy ( CRRT ) , time enrollment Evidence acute blood loss within 1 week enrollment active diagnosis acute chronic blood loss hemolysis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>Anemia</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>erythropoetin</keyword>
	<keyword>Epoetin alfa</keyword>
	<keyword>erythropoetin recombinant</keyword>
	<keyword>Critical care</keyword>
	<keyword>critical illness , intensive care ,</keyword>
</DOC>